Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2023 / N 1

Терапия развернутых стадий болезни Паркинсона. Кому и когда назначать инвазивную терапию?
Е.А. Катунина, Н.Н. Шипилова, З.С. Исаева

Список литературы

1. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease study 2016. The Lancet. Neurology 2018 Nov;17(11):939-53.
2. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease study 2015. The Lancet. Neurology 2017 Nov;16(11):877-97.
3. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Movement Disorders 2014 Nov;29(13):1583-90.
4. Dorsey ER, Bloem BR. The Parkinson pandemic – a call to action. JAMA Neurology 2018 Jan;75(1):9-10.
5. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA 2020 Feb;323(6):548-60.
6. Министерство здравоохранения; Всероссийское общество неврологов; Некоммерческое партнерство “Национальное общество по изучению болезни Паркинсона и расстройств движений”; Межрегиональная общественная организация “Об­щест­во специалистов по функциональной и стереотаксической нейрохирургии”; Общероссийская общественная организация “Союз реабилитологов России”; Ассоциация нейрохирургов России. Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Клинические рекомендации. Кодирование по Международной статистической классификации болезней и проблем, связанных со здоровьем: G20. G21.1. G21.2. G21.4. G23.1–23.3. G23.8. Возрастная категория: взрослые. Год утверждения: 2021. Пересмотр не позднее: 2023. М., 2021. 301 с. Доступно по: https://cr.minzdrav.gov.ru/recomend/716_1 Ссылка активна на 03.04.2023.
7. Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Movement Disorders 1987;2(2):73-91.
8. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Movement Disorders 2005 Mar;20(3):342-4.
9. Linazasoro G; Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson’s disease. Journal of Neurology 2004 Mar;251(3):335-9.
10. Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C; Pramipexole Switch Study Group. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Movement Disorders 2010 Oct;25(14):2326-32.
11. Schrag A, Quinn N. Dyskinesia and motor fluctuations in Parkinson’s disease: a community-based study. Brain 2000 Nov;123(Pt 11):2297-305.
12. Olanow CW. The scientific basis for the current treatment of Parkinson’s disease. Annual Review of Medicine 2004;55:41-60.
13. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson’s disease. Journal of Neural Transmission (Vienna, Austria: 1996) 2005 Mar;112(3):359-91.
14. Schapira A. Present and future drug treatment for Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry 2005 Nov;76(11):1472-8.
15. Lees AJ. The on-off phenomenon. Journal of Neurology, Neurosurgery & Psychiatry 1989 Jun;52(Suppl):29-37.
16. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology, Neurosurgery & Psychiatry 2003 Aug;74(8):1071-9.
17. Chang Y, Wang LB, Li D, Lei K, Liu SY. Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Annals of Medicine 2017 Aug;49(5):421-34.
18. Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson’s disease. The Cochrane Database of Systematic Reviews 2000;2000(3):CD002261.
19. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007 Apr;68(16):1262-7.
20. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High-dose ropinirole in advanced Parkinson’s disease with severe dyskinesias. Clinical Neuropharmacology 2003 May-Jun;26(3):146-50.
21. Giménez-Roldán S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson’s disease: open label pilot responses to three different dose-ratios. Clinical Neuropharmacology 2001 Nov-Dec;24(6):346-51.
22. Pajo AT, Espiritu AI, Jamora RDG. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Neurodegenerative Disease Management 2019 Aug;9(4):205-15.
23. Катунина Е.А., Титова Н.В. Леводопа-индуцированные дискинезии при болезни Паркинсона: патогенез, клиника, подходы к лечению. Фарматека 2014;10:58-69.
24. Катунина Е.А., Титова Н.В., Шипилова Н.Н., Казаков А.Ю., Макарова А.А. Современный взгляд на проблему лекарст­венных дискинезий и подходы к терапии. Нервные болезни 2017;2:10-20.
25. Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurologica Scandinavica. 2017 Nov;136(5):378-85.
26. Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM, Laurent A, Gentil M, Perret J. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotactic and Functional Neurosurgery 1994;62(1-4):76-84.
27. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England Journal of Medicine 1998 Oct;339(16):1105-11.
28. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. The Lancet 1995 Jan;345(8942):91-5.
29. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson’s disease. The Lancet 1997 Dec;350(9092):1676.
30. Гусев Е.И., Катунина Е.А., Титова Н.В. Глубокая стимуляция мозга в лечении болезни Паркинсона. Вестник Росздравнадзора 2016;6:54-60.
31. Siegfried J. Therapeutic stereotactic procedures on the thalamus for motor movement disorders. Acta Neurochirurgica 1993;124(1):14-8.
32. Kumar R, Lang AE, Rodriguez-Oroz MC, Lozano AM, Limousin P, Pollak P, Benabid AL, Guridi J, Ramos E, van der Linden C, Vandewalle A, Caemaert J, Lannoo E, van den Abbeele D, Vingerhoets G, Wolters M, Obeso JA. Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson’s disease. Neurology 2000;55(12 Suppl 6):S34-9.
33. Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund HJ. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Annals of Neurology 2004 Jun;55(6):871-5.
34. Loher TJ, Burgunder JM, Pohle T, Weber S, Sommerhalder R, Krauss JK. Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study. Journal of Neurosurgery 2002 May;96(5):844-53.
35. Rodrigues JP, Walters SE, Watson P, Stell R, Mastaglia FL. Globus pallidus stimulation in advanced Parkinson’s disease. Journal of Clinical Neuroscience 2007 Mar;14(3):208-15.
36. Handbook of essential tremor and other tremor disorders. Lyons KE, Pahwa R, editors. Boca Raton, Fl: Taylor & Francis; 2005. 416 p.
37. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends in Neurosciences 1990 Jul;13(7):281-5.
38. Limousin P, Greene J, Pollak P, Rothwell J, Benabid AL, Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson’s disease. Annals of Neurology 1997 Sep;42(3):283-91.
39. Metman LV, Slavin KV. Advances in functional neurosurgery for Parkinson’s disease. Movement Disorders 2015 Sep;30(11):1461-70.
40. Georgiev D, Mencinger M, Rajnar R, Mušič P, Benedičič M, Flisar D, Bošnjak R, Mehrkens J, Pirtošek Z, Boetzel K, Trošt M. Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson’s disease: a four-year observational, prospective study. Parkinsonism & Related Disorders 2021 Aug;89:13-6.
41. Dafsari HS, Reddy P, Herchenbach C, Wawro S, Petry-Schmelzer JN, Visser-Vandewalle V, Rizos A, Silverdale M, Ashkan K, Samuel M, Evans J, Huber CA, Fink GR, Antonini A, Chaudhuri KR, Martinez-Martin P, Timmermann L; IPMDS Non-Motor Symptoms Study Group. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson’s disease. Brain Stimulation 2016 Jan-Feb;9(1):78-85.
42. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Movement Disorders 2006 Jun;21(Suppl 14):S290-304.
43. Ngoga D, Mitchell R, Kausar J, Hodson J, Harries A, Pall H. Deep brain stimulation improves survival in severe Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry 2014 Jan;85(1):17-22.
44. Deep-Brain Stimulation for Parkinson’s Disease Study Group; Obeso JA, Olanow CW, Rodriguez-Oroz MC, Krack P, Kumar R, Lang AE. Stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. The New England Journal of Medicine 2001 Sep;345(13):956-63.
45. Mogilner AY, Sterio D, Rezai AR, Zonenshayn M, Kelly PJ, Beric A. Subthalamic nucleus stimulation in patients with a prior pallidotomy. Journal of Neurosurgery 2002 Apr;96(4):660-5.
46. Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nature Review. Neurology 2010 Sep;6(9):487-98.
47. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England Journal of Medicine 2003 Nov;349(20):1925-34.
48. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, Chabardes S, Foote K, Benabid AL, Pollak P. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry 2004 Jun;75(6):834-9.
49. Czernecki V, Schüpbach M, Yaici S, Lévy R, Bardinet E, Yelnik J, Dubois B, Agid Y. Apathy following subthalamic stimulation in Parkinson’s disease: a dopamine responsive symptom. Movement Disorders 2008 May;23(7):964-9.
50. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, Kloss M, Schnitzler A, Wojtecki L, Bötzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. The Lancet. Neurology 2008 Jul;7(7):605-14.
51. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schüpbach M, D’Ambrosia J, Thobois S, Tamma F, Herzog J, Speelman JD, Samanta J, Kubu C, Rossignol H, Poon YY, Saint-Cyr JA, Ardouin C, Moro E. A multicenter study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 2008 Oct;131(Pt 10):2720-8.
52. Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, Krack P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013 May;136(Pt 5):1568-77.
53. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005 Jun;128(Pt 6):1314-22.
54. Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain 2010 Apr;133(Pt 4):1111-27.
55. Castrioto A, Volkmann J, Krack P. Postoperative management of deep brain stimulation in Parkinson’s disease. Handbook of Clinical Neurology 2013;116:129-46.
56. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? Journal of Neurology, Neurosurgery & Psychiatry 2000 Sep;69(3):308-12.
57. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. The Lancet. Neurology 2009 Dec;8(12):1140-9.
58. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. The Lancet. Neurology 2009 May;8(5):464-74.
59. Weintraub D, Koester J, Potenza M, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology 2010 May;67(5):589-95.
60. Шипилова Н.Н., Титова Н.В., Кокаева З.Г., Федосова А.С., Климов Е.А., Катунина Е.А. Клинико-генетическое исследование импульсивно-компульсивных расстройств у больных болезнью Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова 2018;118(10):4-9.
61. St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010 Oct;75(14):1292-9.
62. Ossig C, Reichmann H. Treatment of Parkinson’s disease in the advanced stage. Journal of Neural Transmission (Vienna, Austria: 1996) 2013 Apr;120(4):523-9.
63. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews. Neurology 2019 Apr;15(4):234-42.
64. Morgante L, Morgante F, Moro E, Epifanio A, Girlanda P, Ragonese P, Antonini A, Barone P, Bonuccelli U, Contarino MF, Capus L, Ceravolo MG, Marconi R, Ceravolo R, D’Amelio M, Savettieri G. How many Parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism & Related Disorders 2007 Dec;13(8):528-31.
65. Fasano A, Gurevich T, Jeck R, Kovács N, Svenningsson P, Szász J, Parra JC, Bergmann L, Johnson A, Sanchez-Soliño O, Tang Z, Vela-Desojo L. Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study. Movement Disorders 2021 Aug;36(8):1853-62.
66. Standaert D, Patel V, Snedecor SJ, Thakkar S, Jalundhwala YJ, Kukreja P, Kratochvil D, Bao Y, Pahwa R. Impact of carbidopa-levo­dopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson’s disease: results from a pooled meta-analysis. Parkinsonism & Related Disorders 2021 May;86:52-7.
67. Espay AJ, Vanagunas AD, Hauser RA, Fernandez HH, Standaert DG, Odin P, Pritchett Y. Levodopa-carbidopa intestinal gel in Parkinson’s disease patients with severe motor fluctuations: interim safety and motor-symptom endpoints in an ongoing, open-label study. Movement Disorder Society Annual Meeting 2012 June 17–21, Dublin, Ireland.
68. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. The Lancet. Neurology 2014 Feb;13(2):141-9.
69. Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P; GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism & Related Disorders 2017 Dec;45:13-20.
70. Slevin JT, Fernandez HH, Zadikof C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. Parkinsonism & Related Disorders 2015;5(1):165-74.
71. Freire-Alvarez E, Kurča E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sánchez-Soliño O, Barbato LM. Levodopa-carbidopa intestinal gel reduces dyskinesia in Parkinson’s disease in a randomized trial. Movement Disorders 2021 Nov;36(11):2615-23.
72. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W; GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism & Related Disorders 2015 Mar;21(3):231-5.
73. Timpka JF, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, Antonini A, Chaudhuri KR. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson’s disease. Acta Neurologica Scandinavica 2016 Jun;133(6):451-8.
74. Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Zangaglia R, Bentivoglio A, Eleopra R, Gualberti G, Melzi G, Antonini A. Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. Journal of Neurology 2019 Sep;266(9):2164-76.
75. Antonini A, Fung VSC, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Movement Disorders 2016 Apr;31(4):530-7.
76. Krüger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, Stefani A, Sensken SC, Parra JC, Onuk K, Yegin A, Antonini A. An observational study of the effect of levodopa carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson’s disease patients. Advances in Therapy 2017 Jul;34(7):1741-52.
77. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. Intrajejunal levo­dopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders 2009 Jul;24(10):1468-74.
78. ClinicalTrials.gov. A study to examine the effect of Levodopa-Carbidopa Intestinal Gel (LCIG) therapy relative to that of Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) associated with advanced Parkinson’s Disease (PD). ClinicalTrials.gov Identifier: NCT02549092. Information provided by AbbVie. Last update posted 2022 Nov 22. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02549092 Accessed 2023 Apr 03.
79. Chaudhuri KR, Healy DG, Schapira AHV; National Institute for Clinical Excellence. Nonmotor symptoms of Parkinson’s disease: diagnosis and management. The Lancet. Neurology 2006 Mar;5(3):235-45.
80. Chaudhuri KR, Antonini A, Pahwa R, Odin P, Titova N, Thakkar S, Snedecor SJ, Hegde S, Alobaidi A, Parra JC, Zadikoff C, Bergmann L, Standaert DG. Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-month follow-up. Journal of Parkinson’s Disease 2022;12(7):2071-83.
81. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005 Jan;64(2):216-23.
82. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurologica Scandinavica 2001 Dec;104(6):343-8.
83. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clinical Neuropharmacology 2008 Mar-Apr;31(3):63-73.
84. Carter JH, Stewart BJ, Archbold PG, Inoue I, Jaglin J, Lannon M, Rost-Ruffner E, Tennis M, McDermott MP, Amyot D, Barter R, Cornelius L, Demong C, Dobson J, Duff J, Erickson J, Gardiner N, Gauger L, Gray P, Kanigan B, Kiryluk B, Lewis P, Mistura K, Malapira T, Zoog K. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s Study Group. Movement Disorders 1998 Jan;13(1):20-8.
85. Титова Н.В., Катунина Е.А. Современные возможности улучшения качества жизни пациентов на поздних стадиях болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(3):94-100.
86. Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced Parkinson’s disease. Movement Disorders 2011 Mar;26(10):664-70.
87. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Movement Disorders 2009 May;24(7):993-1000.
88. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 1996 Apr;46(4):1062-5.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]